| 151 |
Bunyavirus recomLine IgM |
A-892v3 |
| 152 |
Buprenorphin im Urin (CEDIA), semiquantitativ |
A-404v4 |
| 153 |
Bupropion |
F-1344v1 |
| 154 |
C1-Esterase Inhibitor-Ak |
F-1763v1 |
| 155 |
C1-Esterase-Inhibitor (Aktivität) |
F-1358v1 |
| 156 |
C1-Esterase-Inhibitor-Protein |
A-778v5 |
| 157 |
C1q-Antikörper |
F-1714v1 |
| 158 |
C3d-Komplement |
F-1771v1 |
| 159 |
C3-Komplement |
A-194v5 |
| 160 |
C3-Nephris-Faktor |
F-1777v1 |
| 161 |
C4-Komplement |
A-195v6 |
| 162 |
CA 125 (Cancer Antigen 125) |
A-594v4 |
| 163 |
CA 15-3 |
A-595v4 |
| 164 |
CA 19-9 |
A-596v4 |
| 165 |
CA 72-4 |
A-174v6 |
| 166 |
Calcitonin |
A-173v5 |
| 167 |
Calcium |
A-306v5 |
| 168 |
Calcium-Kanal N-Typ IgG Ak |
F-1322v1 |
| 169 |
Calcium-Kanal PQ-Typ IgG Ak |
F-1321v1 |
| 170 |
Calprotectin |
F-1376v1 |
| 171 |
Calprotectin im Stuhl |
A-1222v6 |
| 172 |
Campylobacter IgA Ak |
A-860v5 |
| 173 |
Campylobacter IgG Ak |
A-323v6 |
| 174 |
C-ANCA |
A-428v4 |
| 175 |
Candida IgG Ak |
A-627v6 |
| 176 |
Candida IgM Ak |
A-858v5 |
| 177 |
Cannabidiol (quant.) |
F-1739v1 |
| 178 |
Cannabinoide i. Mekonium (qual.) |
F-1517v1 |
| 179 |
Cannabinoide im Urin (THC- COOH) |
A-950v3 |
| 180 |
Cannabinoide (qual.) |
F-1450v1 |
| 181 |
Cannabis im Urin (DRI), semiquantitativ |
A-403v4 |
| 182 |
Carbamazepin |
A-231v4 |
| 183 |
Carbapenemaseabklärung |
F-1351v1 |
| 184 |
Carboanhydrase II IgG AK |
F-1524v1 |
| 185 |
Carcinoembryonales Ag (CEA) |
F-1461v1 |
| 186 |
Carcinoembryonales Antigen (CEA) |
A-600v4 |
| 187 |
Cardiolipin IgG |
A-703v5 |
| 188 |
Cardiolipin IgM |
A-1062v4 |
| 189 |
Cariprazin |
F-1411v1 |
| 190 |
Carnitin (frei) |
F-1791v1 |
| 191 |
Carnitin (gesamt) |
F-1790v1 |
| 192 |
CASPR2 IgG Ak |
F-1313v1 |
| 193 |
CCP |
A-368v4 |
| 194 |
CDT |
A-779v5 |
| 195 |
Cefepim |
A-1615v1 |
| 196 |
Cenobamat |
F-1829v1 |
| 197 |
Chlamydia pneumoniae IgA Ak |
A-1212v3 |
| 198 |
Chlamydia pneumoniae IgG Ak |
A-1211v3 |
| 199 |
Chlamydia trachomatis IgA Ak |
A-1210v3 |
| 200 |
Chlamydia trachomatis IgG Ak |
A-1209v3 |